Calyxt Completes New Scientific Advisory Board with Key Appointments
World-Renowned Plant-Biochemistry Experts Named to Calyxt's Scientific Advisory Board Chaired by Company Co-Founder Dan Voytas, Ph.D.
New Strategic Initiative to Identify High Value Plant-Derived Products Utilizing Calyxt's Proprietary Innovation Platform
ROSEVILLE, MN / ACCESSWIRE / March 2, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, has completed key appointments to its previously announced Scientific Advisory Board (SAB) to identify high value plant-derived product targets that will be produced utilizing Calyxt's proprietary innovation platform.
The SAB will provide guidance for Calyxt to leverage and grow the business in new directions and will explore opportunities in plant-derived ingredients for therapeutics, cosmetics, advanced materials, fragrance, flavor, color, and more. The SAB will identify both near-term opportunities and long-term technological breakthroughs, some of which may be realized through partnerships.
The Calyxt Scientific Advisory Board members include:
- Dan Voytas, Ph.D., Calyxt Scientific Advisory Board Chair and Professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota
- Anne Osbourn, Ph.D., Group Leader at the John Innes Center
- Elizabeth Sattely, Ph.D., HHMI Investigator and Associate Professor of Chemical Engineering, Stanford University
- Paul Bernasconi, Ph.D., Former Global Function Head for Molecular Biology at BASF Biosciences
"Gene editing is transforming life sciences and I'm excited to lead the SAB's ideation to unleash the remarkable capacity of plants to produce complex metabolites with high value. These products will deliver enhanced benefits for people and the planet," said Dan Voytas, Ph.D., Calyxt scientific advisory board chair.
"The capabilities that we're developing within Calyxt have broad applications, allowing us to dream big. We're excited to leverage the remarkable expertise of this SAB to focus Calyxt's innovation engine on realizing new opportunities," said Yves Ribeill, Ph.D., executive chairman of Calyxt.
Dan Voytas, Ph.D., the inventor of TALEN® technology and a co-founder of Calyxt, will immediately assume his new role as Chair of the newly established Scientific Advisory Board.
Calyxt (NASDAQ:CLXT), based in Roseville, Minnesota, is a technology company with a mission to deliver plant-based innovations for a better world. Founded in 2010, Calyxt uses its proprietary TALEN® gene editing technology to work with world-class partners via technology licensing, product development, and seed sale arrangements to revolutionize the way the world uses plants to solve problems. For further information, please visit our website at www.calyxt.com.
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "estimates," "expects," "targets," "intends," "may," "might," "plans," "potential," "predicts," "projects," "should," or "will," the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about our ideation and product development efforts, our business model and go-to-market strategies, and growth strategies.
These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our or our collaborators' key facilities; changes in customer preferences and market acceptance of our or our partners' products; competition for collaboration partners and licensees and the successful execution of collaborations and licensing agreements; the impact of adverse events during development; the impact of improper handling of our product candidates by unaffiliated third parties during development; failures by third-party contractors; inaccurate demand forecasting; the effectiveness of commercialization efforts by commercial partners or licensees; our ability to collect accounts receivable; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed under the caption entitled "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings on Form 10-Q or 8-K with the U.S. Securities and Exchange Commission.
Any forward-looking statements made by us are based only on information currently available to us when, and speaks only as of the date, such statement is made. Except as otherwise required by securities and other applicable laws we do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change.
For further information, please contact:
Calyxt Media Contact:
Trina Lundblad, Director of Corporate Communications
Calyxt Investor Relations Contact:
Chris Tyson, Managing Director
MZ Group - MZ North America
View source version on accesswire.com:
Released March 2, 2021